Ki-67 expression as a prognostic factor in diffuse large B-cell lymphoma patients treated with rituximab plus CHOP

Dok Hyun Yoon, Dae Ro Choi, Heui June Ahn, Shin Kim, Dae Ho Lee, Sang We Kim, Bong Hee Park, Sun Och Yoon, Jooryung Huh, Sang Wook Lee, Cheolwon Suh

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Background: Assessment of tumor cell proliferation based on Ki-67 expression yielded conflicting prognostic predictions of patients with diffuse large B-cell lymphoma (DLBCL). The introduction of rituximab to the DLBCL treatment regime has led to alterations in the significance of previous prognostic factors. Methods: We analyzed Ki-67 expression and its correlation with prognosis in 144 patients with DLBCL treated with rituximab plus CHOP (R-CHOP) between July 2003 and January 2008. Results: The complete response (CR) rates following R-CHOP administration were not significantly different, based on Ki-67 expression status (P = 0.104). However, higher rates of relapse were observed in the high Ki-67 expression group (Ki-67 ≥ 85%, n = 46) with 25.0%, compared to 10.0% in the low Ki-67 expression group (Ki-67 < 85%, n = 88) (P = 0.040). The 2-yr event-free survival (EFS) rates were 44.3% and 74.1% in the high and low Ki-67 expression groups, respectively (P = 0.011). The 2-yr overall survival (OS) rate was 66.4% in the high Ki-67 expression group and 82.2% in the low Ki-67 expression group (P = 0.016). In multivariate analysis, Ki-67 expression was a significant prognostic factor for EFS [hazard ratio (HR) = 2.909; 95% confidence interval (CI) 1.261-6.708; P = 0.012]. Ki-67 was associated with OS but with borderline significance (HR = 2.876; 95% CI, 0.972-8.508; P = 0.056). Conclusion: Elevated Ki-67 expression seems to be associated with higher relapse after CR and inferior EFS in patients with DLBCL treated with R-CHOP.

Original languageEnglish
Pages (from-to)149-157
Number of pages9
JournalEuropean Journal of Haematology
Volume85
Issue number2
DOIs
Publication statusPublished - 2010 Aug 1

All Science Journal Classification (ASJC) codes

  • Hematology

Fingerprint Dive into the research topics of 'Ki-67 expression as a prognostic factor in diffuse large B-cell lymphoma patients treated with rituximab plus CHOP'. Together they form a unique fingerprint.

  • Cite this

    Yoon, D. H., Choi, D. R., Ahn, H. J., Kim, S., Lee, D. H., Kim, S. W., Park, B. H., Yoon, S. O., Huh, J., Lee, S. W., & Suh, C. (2010). Ki-67 expression as a prognostic factor in diffuse large B-cell lymphoma patients treated with rituximab plus CHOP. European Journal of Haematology, 85(2), 149-157. https://doi.org/10.1111/j.1600-0609.2010.01467.x